Stay updated on Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.

Latest updates to the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now shows Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.0%

- Check21 days agoChange DetectedAdded a note that PubMed-derived publications are automatically filled for the study page and may not be about the study, and updated the revision to v3.3.1; removed the previous PubMed note and Revision: v3.2.0.SummaryDifference0.0%

- Check28 days agoChange DetectedDeleted the generic government operating status notice from the page, which does not affect the study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedThe new screenshot shows the same study details and locations with only minor formatting or rendering differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check50 days agoChange DetectedAdded Cali, Colombia, 760043 as a study location and removed Santiago de Cali, Colombia, 760043 from the locations list. This updates the Contacts and Locations section to reflect current recruitment sites.SummaryDifference0.1%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference2%

Stay in the know with updates to Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.